|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Maemondo M, Inoue A, Kobayashi K, Sugawara
S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I,
et al: Gefitinib or chemotherapy for non-small-cell lung cancer
with mutated EGFR. N Engl J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mitsudomi T, Morita S, Yatabe Y, Negoro S,
Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, et
al: Gefitinib versus cisplatin plus docetaxel in patients with
non-small-cell lung cancer harbouring mutations of the epidermal
growth factor receptor (WJTOG3405): An open label, randomised phase
3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
First-line crizotinib versus chemotherapy in ALK-positive lung
cancer. N Engl J Med. 371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Alamgeer M, Peacock CD, Matsui W, Ganju V
and Watkins DN: Cancer stem cells in lung cancer: Evidence and
controversies. Respirology. 18:757–764. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shien K, Toyooka S, Yamamoto H, Soh J,
Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, et al:
Acquired resistance to EGFR inhibitors is associated with a
manifestation of stem cell-like properties in cancer cells. Cancer
Res. 73:3051–3061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sugano T, Seike M, Noro R, Soeno C, Chiba
M, Zou F, Nakamichi S, Nishijima N, Matsumoto M, Miyanaga A, et al:
Inhibition of ABCB1 overcomes cancer stem cell-like properties and
acquired resistance to MET inhibition in non-small lung cancer. Mol
Cancer Ther. 14:2433–2440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kalikaki A, Koutsopoulos A, Hatzidaki D,
Trypaki M, Kontopodis E, Stathopoulos E, Mavroudis D, Georgoulias V
and Voutsina A: Clinical outcome of patients with non-small cell
lung cancer receiving front-line chemotherapy according to EGFR and
K-RAS mutation status. Lung Cancer. 69:110–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L;
International Association for the Study of Lung Cancer
International Staging Committee, : Participating Institutions: The
IASLC Lung Cancer Staging Project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
World Medical Association, . World Medical
Association Declaration of Helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McCarty KS, Miller LS, Cox EB, Konrath J
and McCarty KS Sr: Estrogen receptor analyses. Correlation of
biochemical and immunohistochemical methods using monoclonal
antireceptor antibodies. Arch Pathol Lab Med. 109:716–721.
1985.PubMed/NCBI
|
|
13
|
Noro R, Seike M, Zou F, Soeno C, Matsuda
K, Sugano T, Nishijima N, Matsumoto M, Kitamura K, Kosaihira S, et
al: MET FISH-positive status predicts short progression-free
survival and overall survival after gefitinib treatment in lung
adenocarcinoma with EGFR mutation. BMC Cancer. 15:312015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Leung EL, Fiscus RR, Tung JW, Tin VP,
Cheng LC, Sihoe AD, Fink LM, Ma Y and Wong MP: Non-small cell lung
cancer cells expressing CD44 are enriched for stem cell-like
properties. PLoS One. 5:e140622010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhu WY, Hunag YY, Liu XG, He JY, Chen DD,
Zeng F, Zhou JH and Zhang YK: Prognostic evaluation of CapG,
gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung
cancer. Anat Rec (Hoboken). 295:208–214. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seike M, Yanaihara N, Bowman ED, Zanetti
KA, Budhu A, Kumamoto K, Mechanic LE, Matsumoto S, Yokota J,
Shibata T, et al: Use of a cytokine gene expression signature in
lung adenocarcinoma and the surrounding tissue as a prognostic
classifier. J Natl Cancer Inst. 99:1257–1269. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sharom FJ: ABC multidrug transporters:
Structure, function and role in chemoresistance. Pharmacogenomics.
9:105–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Moitra K, Lou H and Dean M: Multidrug
efflux pumps and cancer stem cells: Insights into multidrug
resistance and therapeutic development. Clin Pharmacol Ther.
89:491–502. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
O'Neill AJ, Prencipe M, Dowling C, Fan Y,
Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran
C, et al: Characterisation and manipulation of docetaxel resistant
prostate cancer cell lines. Mol Cancer. 10:1262011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Szakács G, Paterson JK, Ludwig JA,
Booth-Genthe C and Gottesman MM: Targeting multidrug resistance in
cancer. Nat Rev Drug Discov. 5:219–234. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu Y, Liu C, Nadiminty N, Lou W, Tummala
R, Evans CP and Gao AC: Inhibition of ABCB1 expression overcomes
acquired docetaxel resistance in prostate cancer. Mol Cancer Ther.
12:1829–1836. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Leonard GD, Fojo T and Bates SE: The role
of ABC transporters in clinical practice. Oncologist. 8:411–424.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Szilvassy SJ, Humphries RK, Lansdorp PM,
Eaves AC and Eaves CJ: Quantitative assay for totipotent
reconstituting hematopoietic stem cells by a competitive
repopulation strategy. Proc Natl Acad Sci USA. 87:pp. 8736–8740.
1990; View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eramo A, Lotti F, Sette G, Pilozzi E,
Biffoni M, Di A, Conticello C, Ruco L, Peschle C and De Maria R:
Identification and expansion of the tumorigenic lung cancer stem
cell population. Cell Death Differ. 15:504–514. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak
J, Xing L, Wang H, Liu Z, Su Y, Stass SA and Katz RL: Aldehyde
dehydrogenase 1 is a tumor stem cell-associated marker in lung
cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Karamboulas C and Ailles L: Developmental
signaling pathways in cancer stem cells of solid tumors. Biochim
Biophys Acta. 1830:2481–2495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takebe N and Ivy SP: Controversies in
cancer stem cells: Targeting embryonic signaling pathways. Clin
Cancer Res. 16:3106–3112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou H, Ma H, Wei W, Ji D, Song X, Sun J,
Zhang J and Jia L: B4GALT family mediates the multidrug resistance
of human leukemia cells by regulating the hedgehog pathway and the
expression of p-glycoprotein and multidrug resistance-associated
protein 1. Cell Death Dis. 4:e6542013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang CC, Yan Z, Zong Q, Fang DD, Painter
C, Zhang Q, Chen E, Lira ME, John-Baptiste A and Christensen JG:
Synergistic effect of the γ-secretase inhibitor PF-03084014 and
docetaxel in breast cancer models. Stem Cells Transl Med.
2:233–242. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shen DY, Zhang W, Zeng X and Liu CQ:
Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein
and reverses multi-drug resistance of cholangiocarcinoma. Cancer
Sci. 104:1303–1308. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Asamura H, Goya T, Koshiishi Y, Sohara Y,
Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, et
al: A Japanese Lung Cancer Registry study: Prognosis of 13,010
resected lung cancers. J Thorac Oncol. 3:46–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lou F, Huang J, Sima CS, Dycoco J, Rusch V
and Bach PB: Patterns of recurrence and second primary lung cancer
in early-stage lung cancer survivors followed with routine computed
tomography surveillance. J Thorac Cardiovasc Surg. 145:75–82. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhu JF, Feng XY, Zhang XW, Wen YS, Lin P,
Rong TH, Cai L and Zhang LJ: Time-varying pattern of postoperative
recurrence risk of early-stage (T1a-T2bN0M0) non-small cell lung
cancer (NSCLC): Results of a single-center study of 994 Chinese
patients. PLoS One. 9:e1066682014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pisters KM, Evans WK, Azzoli CG, Kris MG,
Smith CA, Desch CE, Somerfield MR, Brouwers MC, Darling G, Ellis
PM, et al: Cancer Care Ontario and American Society of Clinical
Oncology adjuvant chemotherapy and adjuvant radiation therapy for
stages I–IIIA resectable non small-cell lung cancer guideline. J
Clin Oncol. 25:5506–5518. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J: International Adjuvant
Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell
lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Douillard J-Y, Rosell R, De Lena M,
Carpagnano F, Ramlau R, Gonzáles-Larriba JL, Grodzki T, Pereira JR,
Le Groumellec A, Lorusso V, et al: Adjuvant vinorelbine plus
cisplatin versus observation in patients with completely resected
stage IB-IIIA non-small-cell lung cancer [Adjuvant Navelbine
International Trialist Association (ANITA)]: A randomised
controlled trial. Lancet Oncol. 7:719–727. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Winton T, Livingston R, Johnson D, Rigas
J, Johnston M, Butts C, Cormier Y, Goss G, Inculet R, Vallieres E,
et al: Vinorelbine plus cisplatin vs. observation in resected
non-small-cell lung cancer. N Engl J Med. 352:2589–2597. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kato H, Ichinose Y, Ohta M, Hata E,
Tsubota N, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N, et al:
A randomized trial of adjuvant chemotherapy with uracil-tegafur for
adenocarcinoma of the lung. N Engl J Med. 350:1713–1721. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pignon JP, Tribodet H, Scagliotti GV,
Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell
R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled
analysis by the LACE Collaborative Group. J Clin Oncol.
26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zheng Z, Chen T, Li X, Haura E, Sharma A
and Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung
cancer. N Engl J Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Friboulet L, Olaussen KA, Pignon JP,
Shepherd FA, Tsao MS, Graziano S, Kratzke R, Douillard JY, Seymour
L, Pirker R, et al: ERCC1 isoform expression and DNA repair in
non-small-cell lung cancer. N Engl J Med. 368:1101–1110. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Noro R, Honda K, Tsuta K, Ishii G,
Maeshima AM, Miura N, Furuta K, Shibata T, Tsuda H, Ochiai A, et
al: Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell
motility gene amplification. Ann Oncol. 24:2594–2600. 2013.
View Article : Google Scholar : PubMed/NCBI
|
